(Q38568463)

4 September 2017

title

Biosimilars in rheumatology: current perspectives and lessons learnt (English)

1 reference

4 September 2017

Thomas Dörner

1

1 reference

4 September 2017

Jonathan Kay

series ordinal

2

1 reference

4 September 2017

language of work or name

English

0 references

publication date

18 August 2015

1 reference

Nature Reviews Rheumatology

4 September 2017

published in

1 reference

4 September 2017

volume

11

1 reference

4 September 2017

issue

12

1 reference

4 September 2017

page(s)

713-724

1 reference

The role of biosimilars in the treatment of rheumatic diseases

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

Who makes it to the base? Selection procedure for a physical activity trial targeting people with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®): a double-blind, single-dose, crossover study in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

Future directions in inflammatory bowel disease management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

Joint position statement by “Sociedad Española de Patología Digestiva” (Spanish Society of Gastroenterology) and “Sociedad Española de Farmacología” (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

21 January 2018

Etanercept biosimilars

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

21 January 2018

Rituximab biosimilars

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

The advent of biosimilar therapies in rheumatology—“O Brave New World”

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

[Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.110

Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26282080

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Quality Of Life Assessments In Korean Patients With Rheumatoid Arthritis (Ra): An Analysis From The Phase Iii Trial To Evaluate Equivalence Of The Etanercept Biosimilar Hd203 And Enbrel® In Combination With Methotrexate (Mtx) In Patients With Ra; Th

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26282080

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRRHEUM.2015.110

1 reference

Dimensions Publication ID

4 September 2017

1027792370

0 references

1 reference